Gilead Sciences (GILD) vs peers
GILD's P/E is not meaningful or is unavailable. Choose another measure to compare peers.
Biotechnology. Updated .
| Stock | P/E | Own 5-year rank |
|---|---|---|
| GILDGilead Sciences | Unavailable | Unranked |
| ABBVAbbVie | 80.5x | 76% |
| VRTXVertex Pharmaceuticals | 30.6x | 79% |
| AMGNAmgen | 27.2x | 78% |
| REGNRegeneron Pharmaceuticals | 19.9x | 67% |
| INCYIncyte | 16.0x | 9% |
| MRNAModerna | Unavailable | Unranked |
How to read this comparison
Up to eight covered companies in the same industry, largest market value first.
P/E divides the share price by earnings per share from the previous twelve months. The middle peer reading excludes GILD and unavailable values.
Own 5-year rank compares each stock with its available weekly readings within the last five years. At least 26 usable weeks are required. A rank of 20% means its current multiple is above 20% of its past readings. It is not a rank against the other stocks in this table.
Dates show data updates; the latest available weekly observation can differ between stocks. Different growth rates, margins and financial risks can explain different multiples. Missing or non-positive denominators are left unranked.